Clinical Trial: Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden

U.S., July 21 -- ClinicalTrials.gov registry received information related to the study (NCT07715396) titled 'Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden' on July 15.

Brief Summary: AIO-TRK/YMO-0425 (High Five) is a phase III, open-label randomized-controlled, multicenter study to evaluate the progression-free survival by the addition of platinum-based chemotherapy to immunotherapy (IO) compared to IO monotherapy in patients with PD-L1high mNSCLC featuring a high tumor burden.

Study Start Date: Oct. 30, 2026

Study Type: INTERVENTIONAL

Condition: Metastatic Non-small Cell Lung Cancer With a High Tumor Burden

Intervention: DRUG: Tislelizumab

Tisleli...